GSK plc (GSK)

GB — Healthcare Sector
Peers: NVS  AZN  RHHBY  BMY  AMGN  MRK  ABBV  GILD  JNJ  SNY  BIIB 

Automate Your Wheel Strategy on GSK

With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GSK
  • Rev/Share 15.5703
  • Book/Share 7.0657
  • PB 4.4
  • Debt/Equity 0.0
  • CurrentRatio 0.8673
  • ROIC 0.1136

 

  • MktCap 65324600452.9292
  • FreeCF/Share 2.2968
  • PFCF 14.0001
  • PE 19.0126
  • Debt/Assets 0.0
  • DivYield 0.0382
  • ROE 0.2418

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade GSK Berenberg Buy Hold -- -- June 3, 2025
Initiation GSK Exane BNP Paribas -- Neutral -- $35.25 April 15, 2025
Initiation GSK Morgan Stanley -- Equal Weight -- -- Feb. 12, 2025

News

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript
GSK
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral

GSK plc (NYSE:GSK ) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDT Company Participants Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Sachin Jain - BofA Securities, Research Division Presentation Sachin Jain BofA Securities, Research Division Sachin Jain here from the European team, Bank of America. It's my pleasure to be hosting Glaxo.

Read More
image for news GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
GSK
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read More
image for news Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Here's Why GSK (GSK) is a Strong Growth Stock
GSK
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why GSK (GSK) is a Strong Growth Stock
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive

GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.

Read More
image for news GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK commits $30bn to US drug research and manufacturing
GSK
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive

GSK PLC (LSE:GSK, NYSE:GSK) will pour $30 billion into research, development and manufacturing in the United States over the next five years, in one of the largest overseas investment programmes announced by a UK-listed company. The commitment includes a fresh $1.2 billion package unveiled today to expand production capacity and adopt artificial intelligence and digital technologies across its American operations.

Read More
image for news GSK commits $30bn to US drug research and manufacturing
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
GSK
Published: September 17, 2025 by: CNBC
Sentiment: Positive

British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.

Read More
image for news UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK, LLY
Published: September 16, 2025 by: WSJ
Sentiment: Positive

GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.

Read More
image for news GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
GSK
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

Read More
image for news Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?
GSK Adds Around $5B in a Month: Here's How to Play the Stock
GSK
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Neutral

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

Read More
image for news GSK Adds Around $5B in a Month: Here's How to Play the Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: August 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
GSK
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
BMY, GSK
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Neutral

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

Read More
image for news BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
GSK
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
GSK opens higher after priority review for new gonorrhoea pill
GSK
Published: August 11, 2025 by: Proactive Investors
Sentiment: Positive

Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher following the US Food and Drug Administration's acceptance of gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea. The decision, based on positive phase III data from the EAGLE-1 trial, sets a target FDA decision date of December 2025.

Read More
image for news GSK opens higher after priority review for new gonorrhoea pill
GSK's antibiotic drug gepotidacin gets priority review by FDA
GSK
Published: August 11, 2025 by: Reuters
Sentiment: Positive

British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral treatment of uncomplicated urogenital gonorrhoea.

Read More
image for news GSK's antibiotic drug gepotidacin gets priority review by FDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
GSK
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

Read More
image for news GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK may have numbers may have been flattered by order timing, says bank
GSK
Published: July 30, 2025 by: Proactive Investors
Sentiment: Neutral

GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range. However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.

Read More
image for news GSK may have numbers may have been flattered by order timing, says bank
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
GSK
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive

GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago.

Read More
image for news GSK (GSK) Q2 Earnings and Revenues Beat Estimates
GSK in talks with Trump administration on U.S. drug pricing, CEO says
GSK
Published: July 30, 2025 by: Reuters
Sentiment: Neutral

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressure from Washington to rein in prices.

Read More
image for news GSK in talks with Trump administration on U.S. drug pricing, CEO says
GSK confident of hitting top end of 2025 targets after strong second quarter
GSK
Published: July 30, 2025 by: Proactive Investors
Sentiment: Positive

GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Specialty Medicines and Vaccines businesses. The pharmaceuticals giant posted sales of £8 billion for the three months to June, up 6% at constant exchange rates.

Read More
image for news GSK confident of hitting top end of 2025 targets after strong second quarter
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
GSK
Published: July 28, 2025 by: Seeking Alpha
Sentiment: Positive

GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management's long-term revenue targets, I see limited near-term catalysts to drive significant EPS or share price appreciation. Financials reveal rising inventories and a stretched balance sheet compared to peers, making the current valuation potentially a value trap.

Read More
image for news GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
GSK's blood cancer drug gets EU approval for multiple myeloma
GSK
Published: July 24, 2025 by: Reuters
Sentiment: Positive

British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.

Read More
image for news GSK's blood cancer drug gets EU approval for multiple myeloma
US FDA extends review of GSK's blood cancer drug
GSK
Published: July 23, 2025 by: Reuters
Sentiment: Neutral

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug Blenrep as a combination treatment, the company said on Wednesday.

Read More
image for news US FDA extends review of GSK's blood cancer drug

About GSK plc (GSK)

  • IPO Date 1980-03-28
  • Website https://www.gsk.com
  • Industry Drug Manufacturers - General
  • CEO Emma Natasha Walmsley
  • Employees 68629

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.